Jones, Bridgette L., MD, MSCR (Research Theme Leader), Professor of Pediatrics at University of Missouri-Kansas City School of Medicine and at Children’s Mercy Kansas City in the Section of Allergy/Asthma/Immunology and Division of Pediatric Clinical Pharmacology and Therapeutic Innovation. Dr. Jones is an allergy/asthma and pediatric clinical pharmacology researcher focused on the evaluation of pharmacologic therapies and treatment response in children with asthma and allergic disease.
Daniel K. Benjamin Jr., MD, PhD, MPH, Kiser-Arena Distinguished Professor of Pediatrics, Duke, and Deputy Director, Duke Clinical Research Institute (DCRI). Dr. Benjamin is the Principal Investigator and Chair of the National Institute of Child Health and Human Development's Pediatric Trials Network. Dr. Benjamin is a pediatric infectious disease physician-scientist, and his research interests include optimizing the safe and effective use of anti-infective agents in the pediatric population.
Balevic, Stephen J., MD, PhD, MHS, Associate Professor of Pediatrics and Medicine, Duke. Dr. Balevic is an adult and pediatric rheumatologist and cares for patients with a wide variety of autoimmune and rheumatic diseases, including systemic lupus, rheumatoid arthritis, juvenile arthritis, vasculitis, and sarcoidosis, among others. He serves as the Director of the Duke Clinical Research Institute Pharmacometrics Center. His research interests are in clinical trials and precision medicine through population pharmacokinetic/pharmacodynamic modeling.
Cohen-Wolkowiez, Michael, MD, PhD, Kiser-Arena Distinguished Professor of Pediatrics and Executive Director of iCubed at the Duke Clinical Research Institute. His research interests include pediatric clinical trial design and the application of pharmacokinetic/pharmacodynamic modeling to optimize drug dosing in the pediatric population.
Gonzalez, Daniel, PharmD, PhD, Associate Professor, Division of Clinical Pharmacology, Department of Medicine, Duke. Dr. Gonzalez's research focuses on applying quantitative pharmacology techniques to characterize the pharmacokinetics and pharmacodynamics of drugs, guide drug dosage selection, and improve drug safety in children.
Hornik, Christoph P., MD, PhD, MPH, Samuel L. Katz Distinguished Professor, Department of Pediatrics, Duke. Dr. Hornik has an advanced degree (PhD) in Pharmaceutical Sciences. His research is focused on applications of pharmacokinetic/pharmacodynamic modeling to promote safe and effective drug use in critically ill children.
Watt, Kevin, MD, PhD, Professor of Pediatrics & Division Chief of Clinical Pharmacology, University of Utah. Dr. Watt leads a research program focused on optimizing drug therapy and outcomes in critically ill children. He is an expert in critical illness physiology, breastmilk pharmacology, advanced pharmacokinetic/pharmacodynamic modeling, and clinical trial design and conduct. In his research, Dr. Watt leverages physiologically-based pharmacokinetic modeling to translate results from bench side ex vivo experiments into bedside dosing recommendations.
Zimmerman, Kanecia O., MD, PhD, MPH (Research Theme Leader), Wilburt C. Davison Distinguished Professor of Pediatrics, Duke. Dr. Zimmerman’s research program leverages pharmacoepidemiologic methods and clinical trials to evaluate the effects of sedatives and analgesics on pediatric pain and sedation. She has served as a scientific advisor to the FDA Office of Pediatric Therapeutics, and she has extensive pediatric drug development experience.
Chambers, Christina, PhD, Professor of Pediatrics, UCSD. Dr. Chambers’ research program has focused on environmental causes of birth defects, other adverse pregnancy outcomes, and childhood disabilities, with a focus on prenatal exposure to recreational substances and medications. She is the principal investigator of Mother-To-Baby Pregnancy Studies, a series of observational cohort studies evaluating the safety of a variety of prenatal environmental exposures.
Greenberg, Rachel, MD, MB, MHS, Professor of Pediatrics, Duke. Dr. Greenberg is a neonatologist, and she has expertise in pharmacoepidemiology and clinical trials. She provides leadership and oversight of the NICHD-funded Pediatric Trials Network, where she oversees the operations of multiple trials in infants and children.
Laughon, Matthew, MD, MPH, Professor, Neonatal-Perinatal Medicine, UNC. Dr. Laughon has expertise in neonatal epidemiology and clinical pharmacology trials (phase I-III) and neonatal lung disease (e.g., bronchopulmonary dysplasia).
O’Shea, Michael, MD, MPH, C. Richard Morris, MD Distinguished Professor of Pediatrics, Neonatal-Perinatal Medicine, UNC. Dr. O’Shea is a neonatologist and epidemiologist, and he has devoted the past three decades to studying the epidemiology and prevention of adverse developmental and health outcomes in children born prematurely. He is the co-principal investigator for the Extremely Low Gestational Age Newborn (ELGAN) cohort in the NIH-sponsored Environmental Influences on Child Health Outcomes (ECHO) Project.
Smith, P. Brian, MD, MPH, Samuel L. Katz Distinguished Professor of Pediatrics, Duke. Dr. Smith’s research is in pediatric drug safety, neonatal pharmacology, and epidemiology of neonatal infections (>250 publications). He has mentored numerous medical students, residents, fellows, and junior faculty. He received the Robert M. Califf Award for Outstanding Mentorship and the Duke University School of Medicine Research Mentoring Award.
Tremoulet, Adriana, MD, MAS (Research Theme Leader), Professor, UCSD. Dr. Tremoulet’s research focuses on repurposing therapeutics in Phase I through III clinical trials, especially in the field of inflammatory and infectious diseases. She is the co-PI of UCSD’s NICHD-funded Pediatric Clinical Pharmacology T32 program, co-director of the NIH-funded Altman Clinical Trials Research Institute KL2 program, and co-PI of the NICHD-funded Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub.
Bode, Lars, PhD, Professor of Pediatrics, UCSD. Dr. Bode is the Director and Chair of Collaborative Human Milk Research at UC San Diego’s Mother-Milk-Infant Center of Research Excellence (MOMI CORE). In addition, he is part of the NICHD-funded MPRINT Center of Excellence in Therapeutics (CET) at UCSD, where he directs the Milk Analytics Core (MAC), which provides consultation as well as an array of analyses that are specifically validated for human milk.
Goldman, Jennifer L., MD, Professor of Pediatrics at the University of Missouri-Kansas City and a member of the Divisions of Clinical Pharmacology, Toxicology and Therapeutic Innovation and Infectious Diseases at Children’s Mercy Kansas City. Dr. Goldman has directed a hospital-wide pediatric adverse drug reaction (ADR) surveillance program at her institution and an NIH-funded research program focused on ADR biomarker detection. Also, recently she has also been working with a large, urban school district to better understand barriers encountered to COVID-19 testing and vaccination in underserved children.
Dorrestein, Pieter C., PhD, Professor, UCSD School of Pharmacy and Pharmaceutical Sciences and Director of the Collaborative Mass Spectrometry Innovation Center. Dr. Dorrestein is a biochemist specializing in mass spectrometry (MS) characterization of metabolic interactions between cell populations. Dr. Dorrestein pioneered new MS technologies defining the distribution of natural products in 2D, 3D, and real-time and computational tools to analyze the metabolomics data. His Global Natural Products Social Molecular Networking (GNPS) analysis ecosystem is the largest metabolomics repository and one of the most widely used analysis infrastructures. He has intricately linked the human and microbiome metabolism to effects on drug pharmacokinetics and action, including antibiotic effects on microbiome and metabolism across the organism.
Heinzen, Erin, PharmD, PhD, Associate Professor, UNC. Dr. Heinzen’s research broadly focuses on neurodevelopment disease genetics, including analyses of the role of germline mutations, somatic mutations, and how regulation of the cellular transcriptome influences the risk and presentation of seizures. The overarching goal of this research is to identify novel treatment approaches for intractable epilepsies and other neurodevelopmental disorders.
Knight, Rob, PhD, Professor of Pediatrics, Bioengineering, and Computer Science & Engineering, UCSD. Dr. Knight’s is an expert on the human microbiome and its role in human nutrition and disease. He has been involved in various large-scale projects, including the Human Microbiome Project and Integrative Human Microbiome Project U54 consortia, the Alzheimer’s Gut Microbiome Project U19 consortium, and co-founding the Earth Microbiome Project and American Gut Project.
Leeder, J. Steven, PharmD, PhD, Professor of Pediatrics and Pharmacology, and the Marion Merrell Dow Endowed Chair in Pediatric Precision Therapeutics, CMKC. His research program utilizes a variety of in vitro and in vivo approaches to characterize the relative contributions of pharmacogenomic variation and changes due to growth and development to observed variability in drug disposition and response in children.